Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShandong Provincial Hospital

About this trial

Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care.

This observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results).

The model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals.

Beyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

significant coronary artery disease (CAD), defined as a stenosis of ˃50% in a major coronary artery

infiltrative disease

valvular cardiomyopathy

arrhythmogenic cardiomyopathy

Trial population

During the study period, patients with dilated cardiomyopathy (DCM) who were seen in the cardiology departments of Shandong Provincial Hospital, Jinan Central Hospital, and Beijing Anzhen Hospital, or referred for cardiac magnetic resonance (CMR) assessment, were prospectively enrolled in the registry at the time of scanning.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • left ventricular ejection fraction

    Other intervention

    HFrEF:LVEF\<40% ; HFmrEF:LVEF40-50%; HFpEF: LVEF\>50%

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

SCD-related events

SCD, appropriate implantable cardioverter-defibrillator shock, and resuscitated cardiac arrest

Time frame
1 year, 3 years, and 5 years after CMR examination

Secondary outcomes

1

heart failure events

heart failure-related death, unplanned heart failure hospitalization, or heart transplantation

Time frame
at 1, 3, and 5 years following CMR

Other outcomes

1

all-cause mortality

Time frame
follow-up will be conducted at 1, 3, and 5 years

Sponsors and contacts

Click on the lead sponsor to view all of their trials.